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Abstract
Human induced pluripotent stem cells (hiPSCs) generated by de-differentiation of adult somatic cells offer potential
solutions for the ethical issues surrounding human embryonic stem cells (hESCs), as well as their immunologic rejection
after cellular transplantation. However, although hiPSCs have been described as ‘‘embryonic stem cell-like’’, these cells have
a distinct gene expression pattern compared to hESCs, making incomplete reprogramming a potential pitfall. It is unclear to
what degree the difference in tissue of origin may contribute to these gene expression differences. To answer these
important questions, a careful transcriptional profiling analysis is necessary to investigate the exact reprogramming state of
hiPSCs, as well as analysis of the impression, if any, of the tissue of origin on the resulting hiPSCs. In this study, we compare
the gene profiles of hiPSCs derived from fetal fibroblasts, neonatal fibroblasts, adipose stem cells, and keratinocytes to their
corresponding donor cells and hESCs. Our analysis elucidates the overall degree of reprogramming within each hiPSC line,
as well as the ‘‘distance’’ between each hiPSC line and its donor cell. We further identify genes that have a similar mode of
regulation in hiPSCs and their corresponding donor cells compared to hESCs, allowing us to specify core sets of donor
genes that continue to be expressed in each hiPSC line. We report that residual gene expression of the donor cell type
contributes significantly to the differences among hiPSCs and hESCs, and adds to the incompleteness in reprogramming.
Specifically, our analysis reveals that fetal fibroblast-derived hiPSCs are closer to hESCs, followed by adipose, neonatal
fibroblast, and keratinocyte-derived hiPSCs.
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Introduction
Human embryonic stem cells (hESCs) are widely recognized as
a precious biological source of pluripotent cells, and hold
tremendous therapeutic promise due to their ability to self-renew,
proliferate, and differentiate [1]. However, the use of human
embryos is controversial, and the problem of immune rejection
following transplantation in patients remains difficult to solve. The
discovery that mouse and human somatic cells can be repro-
grammed into induced pluripotent stem cells (iPSCs) has given
researchers a non-controversial alternative source of pluripotent
human cells. Further, iPSC technology could overcome some of
the obstacles associated with immune rejection after transplanta-
tion[2,3,4,5].
The direct reprogramming of somatic cells to pluripotent state
was accomplished in 2006, when Takahashi and Yamanaka
converted adult mouse fibroblasts to iPSCs through ectopic
expression of a group of transcription factors [6]. Since then, a
plethora of reports have been published showing derivation of
iPSCs from various murine and human tissues [6,7,8,9,10],
including human iPSCs (hiPSCs) that were derived from multiple
cell types [8,9,10,11,12,13,14,15,16,17].
In the journey of reprogramming, cells start from a differen-
tiated state to reach an embryonic-like state after over-expression
of a defined set of transcription factors that act as arbiters in the
journey [6]. But pressing scientific questions remain. For instance,
how close are these iPSCs to their conventional hESC counter-
parts? What is the exact genetic status of these reprogrammed
cells? Do they still bear any ‘‘footprint’’ of their tissue of origin that
may contribute to differences with hESCs [18]? hiPSCs at
different passages have significant differences in gene expression
from hESCs [19], and it has been shown that there is significant
variation in the teratoma forming propensities of iPSCs depending
on the tissue of origin [20,21,22]. With these issues in mind,
Maherali and Hochedlinger published a timely and valuable
review that suggests basic criteria for evaluating the pluripotency
of iPSCs [23]. Hence, as the potential of hiPSCs and their
derivatives for regenerative medicine is being evaluated, it has
become clear that an analysis is needed of the overall state of these
cells, as well as comparisons with other derived lines, in order to
evaluate their safety for regenerative therapy.
Although most publications report that the gene expression
profiles of hiPSCs are ‘‘nearly identical’’ to their embryo-derived
counterparts, hESCs, it is essential to clearly define the differences
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between the two cellular populations, and among the hiPSCs
themselves, could account for incomplete reprogramming. There-
fore, we believe that a careful analysis is necessary in order to
discern whether hiPSCs bear persistent donor cell gene expression
which may interfere with their reversion from somatic cells.
We performed a comprehensive transcriptional analysis of
different hiPSC lines that have been previously reported to be
derived from several different cell sources, using hESCs as a gold
standard. The sum of our analysis has uncovered a persistent gene
expression pattern in hiPSCs that appears to be related to the
specific tissue of origin. Bioinformatic analysis reveals a degree of
incompleteness in reprogramming that results from this residual
gene expression. In the future, further investigation is warranted to
determine whether persistent donor cell gene expression in hiPSCs
could cause functional differences in their pluripotency and
capacity to differentiate into their original cell type rather than
compared to other cell types.
Materials and Methods
Source of Gene Profiles
In order to compute the distance between the ‘‘hiPSC-state’’,
‘‘hESC-state’’, and ‘‘differentiated state’’, we analyzed the
transcriptional profiles of previously reported hiPSC lines
[11,12,15,17] and compared their gene expression data to those
of multiple hESCs and donor cell lines. Gene expression data were
obtained from the Gene Expression Omnibus (GEO) repository
(http://www.ncbi.nlm.nih.gov/geo/), which is currently the
largest fully public gene expression resource. The GEO [24]
repository at the National Center for Biotechnology Information
(NCBI) archives and freely disseminates microarray and other
forms of high-throughput data generated by the scientific
community. Table 1 summarizes the details of the hiPSC lines
considered in our analysis, including the nomenclature we used for
each cell line. The 6 hESC lines considered in our analysis are H1,
H7, H9, H13, H14, and T3, all of which are also derived from
GEO repository.
Microarray Analysis
All gene expression data were reported to be obtained with the
HG-U133plus2 microarray platform (Affymetrix). Note that the
data on adipose stem cell derived-hiPSCs reported by Sun et al.’s
paper [15] used the Agilent 4644 K whole human genome
microarray platform. For our study, we re- hybridized the same
RNA samples to the Affymetrix HG-U133Plus2 chips, and the
expression signals were scanned on an Affymetrix GeneChip
Scanner. All data sets were analyzed using GeneSpring GX 10.0
software (Agilent Technologies, Inc. www.chem.agilent.com).
Gene-level signal estimates were derived from the CEL files.
Summarization of gene expression data was performed by
implementing the robust multichip averaging algorithm, with
subsequent baseline normalization of the log-summarized values
for each probe set to that of the median log summarized value for
the same probe set in the control group. Expression data were then
filtered to remove probe sets for which the signal intensities for all
the treatment groups were in the lowest 20 percentile of all
intensity values. The data were then subjected to analysis of
variance (ANOVA), incorporating the Benjamini–Hochberg FDR
multiple testing correction, with a significance level of P-value
,0.05 to get the differentially expressed genes between different
groups. Probe sets were further filtered on the basis of a fold-
change cut off of 2.0. Hierarchical clustering was performed by
complete linkage [25] and uncentered correlation using the open
source clustering software Cluster 3.0; results were visualized using
Java TreeView [26].
Distance Metric
We have defined the distance metric between two groups of cells
to be the percentage of genes that are differentially expressed
between them; thus, two ‘‘closer’’ groups will have a lower
percentage of genes that are different between them, and vice versa.
After gene expression data from all groups (hESC, hiPSCs and
donor cells) were subjected to the same statistical screening
criterion (P-value cut off ,0.05 and a fold-change cut off of 2.0),
we then calculated the distances among them. This gives a clear
estimation of the status of the hiPSCs and donor cells with respect
to hESCs. Furthermore, it also gives a clear idea of how closer
each hiPSCs are from their corresponding donor cells compared to
other donor cell types. To calculate the relative distances among
hESCs, hiPSCs, and donor cells, we considered 1 to be the total
proportion of genes that are significantly different between starting
position (donor cells) and final position (hESC). With respect to
this, we have calculated the proportion of the genes different
between hiPSC and donor cells, and between hiPSCs and hESCs.
This provides the status of reprogramming of hiPSCs relative to
the donor cells and hESCs. Note that at present there is no
uniformly accepted, epistemologically pure meaning of ‘distances’
between gene expression profiles, and different metrics are useful
in different situations. Hence, it is important to choose a metric
that is intuitively conceivable and has a straightforward definition,
as is the case with the measure used here. However, in future
studies, it will have to be compared to other distance measures
addressing the same type of question.
Table 1. Summary of the hiPSC lines used for analyzing donor cell vs. hiPSC relationship.
Donor Cells
Donor cell line
nomenclature
Corresponding iPS cell line
nomenclature Reprogramming method References
Foreskin fibroblast hFFib iPS-hFFib Reprogramming by using non-integrating
oriP/EBNA1-based episomal vectors
[17]
Adipose stem cells hASC iPS-hASC Reprogramming by lentiviral transduction
with Oct4, Sox2, Klf4, and c-MYC
[15]
Neonatal fibroblast hNFib iPS-hNFib Direct delivery of defined reprogramming
proteins.
[12]
Keratinocytes hKT iPS-hKT Reprogramming by retroviral transduction
with Oct4, Sox2, Klf4, and c-Myc
[11]
The six hESC lines used in this study are H1, H7, H9, H13, H14, and T3.
doi:10.1371/journal.pone.0008975.t001
Donor Cell Memory in hiPS Cell
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In order to perform functional annotation of the differentially
expressed genes between different groups, we used Ingenuity
Pathway Analysis (IPA) software. This software assigns biological
functions to genes using the Ingenuity Pathways Knowledge Base
(Ingenuity Systems, Inc., Redwood City, CA). The knowledge
base comprises information about thousands of human, mouse,
and rat genes [27]. This information is used to form networks to
create an ‘interactome’ of genes all involved in specific biological
processes.
Results
The four different human cell sources used in our analysis are
fetal fibroblasts, neonatal fibroblasts, adipose stem cells, and
keratinocytes. Fibroblasts are ubiquitous terminally differentiated
mesenchymal cells with multiple functions during development,
tissue repair, and disease. Further, there are significant gene
expression differences between fetal and neonatal fibroblasts [28].
Human adipose stem cells are a heterogeneous group of
multipotent progenitor cells that are derived from adipose tissue
of adult humans [29] and can differentiate into adipogenic,
osteogenic, chondrogenic, and myogenic cell lineages [30].
Keratinocytes are keratin-dense epithelial cells which generate
the outer protective epidermal barrier of the skin surface and
appendages, a life-long process owing to the presence of self-
renewing keratinocyte stem cells. These cells produce transit-
amplifying cells that subsequently exit the cell cycle as they
terminally differentiate [31]. Hence, it is likely that all these donor
cell types possess their own distinctive epigenetic landscapes based
on various DNA and histone modifications. Here we analyze the
reprogramming status of the hiPSCs derived from these different
types of cell.
Defining hiPSC State Based on the Global Gene
Expression Pattern
To determine the degree of reprogramming within hiPSCs, we
analyzed genome-wide expression patterns in six different hESC
lines (H1, H7, H9, H13, H14, and T3), hiPSCs from fetal
fibroblasts (iPS-hFFib), hiPSCs from neonatal fibroblasts (iPS-
hNFib), hiPSCs from adipose stem cells (iPS-hASC), hiPSCs from
keratinocytes (iPS-hKT), and their corresponding donor cells
(hFFib, hNFib, hASC, and hKT). According to the distance metric
defined in the methods section, a lower percentage of differentially
expressed genes between two groups make them closer compared
to other cell types, and vice versa. The matrix in Figure 1
summarizes the probe sets retained in each groups after ANOVA
analysis with cutoff of P-value ,0.05 and fold-change of $2. After
analyzing the expression difference between hESCs (averaged over
the six different cell lines) and different hiPSC lines derived from
different cell sources, we found that 505, 2571, 5555, and 13670
genes (out of 28322) were significantly different in iPS-hFFib, iPS-
hASC, iPS-hNFib and iPS-hKT, respectively, compared to
hESCs. Furthermore, we compared the gene expression profiles
of the donor cell lines with respect to hESCs, and found that 9059,
13450, 9861, and 15954 genes (out of 28322) were significantly
different in hFFib, hASC, hNFib, and hKT, respectively
(Figure 1).
Figure 2A shows the relative distances between the different
hiPSCs from hESCs, and from donor cells. Hierarchical clustering
(Figure 2B) based on the global gene expression pattern, as well
as distance measures (Figures 3A and 3B), shows the differences
between various hiPSCs and donor cells with respect to hESCs.
These figures show that fetal fibroblast-derived hiPSCs attain a
pluripotent state that is closest to hESCs, whereas keratinocyte-
derived hiPSCs attain a pluripotent state that is farthest from
hESCs. Furthermore, iPS-hASC is the second closest hiPSC state
to hESC, followed by iPS-hNFib. Similarly, we found that
different donor cells have varying distances from hESCs, as shown
in Figure 3B.
The Relationship between hiPSCs and Donor Cells
To look deeper into the hiPSC and donor cell relationship, we
further analyzed the genes that were differentially expressed
between hiPSCs and their donor cells (Figure 3C–3F). Overall,
we found that hiPSCs tend to be closer to their corresponding
donor cell type than to other donor cell types. This pattern
suggests that the expression of genes determining the differenti-
ated state are not completely switched off. In order to determine
the specific subset of genes that have similar modes of regulation
in both hiPSCs and donor cells, we next compared the gene
expression differences between hiPSCs and donor cells with
respect to expression levels in hESCs. These specific gene sets
hold critical clues as to how these hiPSCs retain a ‘‘memory’’ of
their tissue of origin even after undergoing reprogramming.
Within the total set of genes differentially expressed in hiPSCs
and donor cells compared to hESCs, there are gene sets that are
either upregulated or downregulated in both hiPSCs and donor
Figure 1. Matrix showing the number of differentially expressed genes P,0.05 and fold-change $2 across hESCs, hiPSCs, and
donor cell lines.
doi:10.1371/journal.pone.0008975.g001
Donor Cell Memory in hiPS Cell
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expression in between hiPSCs and donor cells. Figure 4 depicts
the distribution of the genes according to their mode of regulation
in each set of hiPSC and corresponding donor cells. Among the
whole set of differentially expressed genes in hiPSCs and donor
cells (compared to hESCs), 77% (51% upregulated+26%
downregulated), 84% (17%+67%), 85% (28%+57%), and 96%
(53%+43%) of the genes have similar modes of expression in iPS-
hFFib, iPS-hASC, iPS-hNFib, and iPS-hKT and their corre-
sponding donor cells, respectively. Thus, the more completely a
somatic cell is reprogrammed, the more likely its resulting hiPSC
will have a distinct gene expression pattern from it. The degree of
reprogramming thus determines the extent of gene expression
differences between the parental and reprogrammed cells. This is
clearly shown in Figure 4, where iPS-hFFib contains the lowest
percentage of similar gene expression modes with its correspond-
ing donor cell (77%), but iPS-hKT has the highest percentage of
similar gene expression modes with its corresponding donor cell
(96%). These results agree with our distance measurements
between different hiPSCs and hESC, shown above (Figure 2A
and 2B).
Upregulated Genes in hiPSCs and Donor Cells
Unsupervised hierarchical clustering of upregulated genes in
hiPSCs and donor cells with respect to hESCs further confirmed the
proximity of hiPSCs to their corresponding cell of origin (Figure 5)
as compared to other donor cell types. For eachset of iPS-donor cell
types, IPA analysis was performed for functional annotation of the
set of upregulated genes (Supplementary Table S1-A to S1-D).
We clarified the role of these genes in various basic processes
(cellular growth and proliferation, tissue development, cellular
function, lipid metabolism, connective tissue development, DNA
repair,cellularmaintenance,etc).Next,weexaminedtheexpression
of fibroblast [32], fat [33,34,35,36], and keratinocyte [37] specific
genes within the upregulated gene sets. We found significant
residual gene expression of fibroblast (Figure 6A), adipocyte
(Figure 6B), and keratinocyte genes (Figure 6C) within their
corresponding hiPSCs. Specifically, fibroblast genes in Figure 6A
such as PLAT and PLAU [32,38] play important roles in
remodeling the extracellular matrix and other functions in the
coagulation system. Other fibroblast genes include CXCL1, which
is involved in cell migration [32], and FOXF1 and FOXP1, which
are forkhead family transcription factors expressed in fibroblasts
Figure 2. Distance between hiPSC, hESC and donor cells. (A) Relative distances of the hiPSC states from the corresponding somatic states
(donor cells), and from the hESC state. (B) Global clustering among hESC, hiPSC, and donor cells.
doi:10.1371/journal.pone.0008975.g002
Donor Cell Memory in hiPS Cell
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inflammatory protein-2, PALLD, and COL1A1 are proteins
expressed in adipocytes [34]. Among the keratinocyte-specific genes
showed in Figure 6C, we found various keratins, transcription
factors, and proteolytic enzymes (and their inhibitors) that are active
in protein turnover and remodeling in keratinocytes, and which are
not common to other cell types [37]. Taken together, our results
demonstrate persistent donor cell gene expression within hiPSCs,
and suggest a failure of reprogramming to efficiently silence the
expression of these somatic genes.
Downregulated Genes in hiPSCs and Donor Cells
Ideally, the path to reprogramming should lead towards
induction of embryonic genes that are responsible for maintaining
an undifferentiated and highly proliferative state. To search for the
embryonic genes that may be incompletely induced within
hiPSCs, we analyzed the downregulated set of genes in both
hiPSCs and their donor cells with respect to hESCs. IPA analysis
was performed to functionally annotate these genes (Supple-
mentary Table S2-A to S2-D). Figure 7 shows the fold-change
of selected genes that are involved in the hESC pluripotency.
Overall, we observed incomplete induction of those genes needed
to maintain an undifferentiated state in fibroblast-derived hiPSCs
(Figure 7A and 7C), fat-derived hiPSCs (Figure 7B), and
keratinocyte-derived hiPSCs (Figure 7D). Specifically, LEFTY1
[40] is significantly downregulated in all the hiPSCs. SOX2 [41],
RIF1, and TP53 [42] exhibited lower expression in all hiPSCs
except iPS-hFFib. Another important embryonic marker gene,
Figure 3. Percentage of differentially expressed genes defines the degree of dissimilarity between hESCs and hiPSCs, hESCs with
the donor cell types, and hiPSCs with the 4 different donor cell types. (A) The distance between hESCs and hiPSCs shows iPS-hFFib to be
closest to hESCs. (B) The distance between hESCs and donor cell types shows hFFib to be closest to hESCs. The distance between hiPSCs and 4
different donor cell types shows (C) iPS-hFFib closest to hFFib; (D) iPS-hASC closest to hASC; (E) iPS-hNFib closest to hNFib; and (F) iPS-hKT closest to
hKT. (Closest grouping is marked with a red circle).
doi:10.1371/journal.pone.0008975.g003
Donor Cell Memory in hiPS Cell
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and iPS-hKT.
Genes with Opposite Expression in hiPSCs and Donor
Cells
While comparing the gene expression profiles of the hiPSCs
and donor cells with respect to hESCs, we came across a set of genes
whose mode of regulation is opposite in hiPSCs as compared to
their donor cells. A closer inspection of these genes, which are
upregulated in hiPSCs but downregulated in donors and vice versa,
reveals a gene expression pattern that is unique for the hiPSC
state derived from different cell sources. Supplementary
Figures S1, S2, S3,a n dS4 show the expression pattern of
these genes that uniquely define each hiPSC state. A detailed
functional annotation of these set of genes is provided in
Supplementary Table S3. These results suggest that hiPSCs
also bear a unique pluripotent cell state as defined by their gene
expression. A detailed inspection of these genes in the future will
Figure 4. Modes of regulation of the differentially expressed genes across different hiPSCs and their corresponding donor cells
compared to hESCs. 77% of the genes have similar expression pattern in iPS-hFFib and hFFib (both upregulated and downreglated). 84% of the
genes have similar expression pattern in iPS-hASC and hASC. 85% of the genes have similar expression pattern in iPS-hNFib and hNFib. 96% of the
genes have similar expression pattern in iPS-hKT and hKT.
doi:10.1371/journal.pone.0008975.g004
Figure 5. Hierarchical clustering of upregulated genes in the hiPSC and donor cells. (A) iPS-hFFib and hFFib. (B) iPS-hASC and hASC. (C)
iPS-hNFib and hNFib. (D) iPS-hKT and hKT. Hierarchical clustering of the upregulated gene expression data shows that hiPSCs cluster more closely to
their corresponding donor cells. This demonstrates that reprogrammed hiPSCs exhibit persistent gene expression from their corresponding donor
cells.
doi:10.1371/journal.pone.0008975.g005
Donor Cell Memory in hiPS Cell
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occur during reprogramming.
Discussion
In addition to their extraordinary potential for the field of
regenerative medicine, hiPSCs provide a powerful system for
studying the regulation of cell-fate transitions and the molecular
programs that permit conversion of one cell type to another. This
field has witnessed rapid growth in the development of safer and
more efficient methods for deriving hiPSCs. However, in order to
take advantage of the power of this new technology, it is important
to more fully understand the character of these cells. We have
executed a detailed investigation into the available transcriptional
profiles of hiPSCs derived from fetal fibroblasts, neonatal
fibroblasts, adipose cells, and keratinocytes. While the overall
transcriptional profiles of hiPSCs share a common ‘‘signature’’
with hESCs, a subset of the gene profiles does suggest retention of
‘‘transcriptional memory’’ of the tissue of origin. Moreover,
another subset of the gene expression pattern identifies the hiPSC
state as unique from that of hESCs as well as from that of donor
cells (Supplemental Figures S1, S2, S3, S4).
However it is possible that some of the results we highlight in
this study may be attributed to varying culturing conditions, cell
passage number, and viral vs. non-viral transfection techniques
used across different laboratories. For example, iPS-hASC (viral),
iPS-hFFib (non-viral), and iPS-hKT (viral) were cultured on
irradiated mouse embryonic fibroblasts (MEFs), and Matrigel was
used later for feeder free culture. In contrast, iPS-hNFib (non-viral)
were cultured on gelatin for feeder-free conditions, while iPS-hKT
were also cultured on human fibroblasts. Irrespective of these
differences, it appears that inherent differences do indeed exist
between hiPSCs and hESCs, and among hiPSCs themselves
[14,19,20]. The variation in the techniques used in reprogram-
ming will be an important consideration for future studies to assess
whether they could significantly impact the overall findings of our
current study. Another important area of concern for this study is
the inherent heterogeneity in stem cell populations [44,45].
Accordingly, incomplete reprogramming of hiPSCs, as demon-
strated by this study, could reflect the fact that the cell population
Figure 6. Residual signatures of the donor cell specific genes (upregulated in both hiPSCs and donor cells compared to hESC) in
hiPSCs. (A) Expression fold-change of fibroblast specific genes in iPS-hFFib, hFFib, iPS-hNFib, and hNFib. (B) Expression fold-change of adipose cell
specific genes in iPS-hASC and hASC. (C) Expression fold-change of keratinocyte specific genes in iPS-hKT and hKT.
doi:10.1371/journal.pone.0008975.g006
Donor Cell Memory in hiPS Cell
PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e8975used in the microarray analysis contained contaminating subpop-
ulations of cells that have not been completely reprogrammed, and
thus give rise to expression signatures of the parental cells [46]. In
other words, individual cells within a heterogeneous population
are either reprogrammed or not, and contamination with the latter
might be a cause of this ‘‘donor cell memory’’. Contamination
with large numbers of incompletely reprogrammed cells may
explain the surprising gene expression results from keratinocyte-
derived iPSCs, which were found to be significantly closer to their
parental cells.
In this study, we sought to understand how similar the
transcriptional profiles of hiPSCs are to their respective donor
cells and to hESCs. Is there an epigenetic memory in hiPSCs that
is related to their tissue of origin? Here, the word ‘‘epigenetic’’ is
used according to Waddington’s definition[47] in which he
describes gene regulation and its consequence for developmental
state, and ‘‘memory’’ refers to the residual gene activity patterns of
the donor state within hiPSCs. Our analysis has clearly revealed
the exact status of different hiPSC lines along the path of
reprogramming: hiPSCs derived from fetal fibroblasts bear a
reprogrammed status closest to hESCs, followed by adipose stem
cells, neonatal fibroblasts, and keratinocyte-derived hiPSCs.
Further, we also show that although most of the original epigenetic
memory was erased in due course of reprogramming, there does
exist some residual memory inherited from the donor cells which
may affect the resulting hiPSCs, suggesting a deficit of repro-
gramming. This residual donor cell gene expression within hiPSCs
may be a cause of the variations in teratoma formation thereafter
[20]. It remains an interesting and pertinent question whether this
epigenetic memory within hiPSCs induces them to differentiate
into their original cell type more easily than into other somatic cell
types.
To conclude, our data suggest that the reprogramming process
does not de-differentiate the somatic cells completely to an ESC-
state; further alteration or modification may therefore be necessary
at the molecular level to reset the somatic nucleus completely to an
embryonic state. This work has attempted to present a
comprehensive analysis of available microarray data of hiPSCs,
and has produced interesting observations that can be used as a
guide for future reprogramming experiments. We hope that our
results will also assist in the selection of optimal sources of donor
cells for generating hiPSCs. Further, investigations to improve our
understanding of the incompleteness in reprogramming will allow
us to modify the methods for deriving hiPSCs best suited for
clinical applications.
Supporting Information
Figure S1 Unique set of genes (A) Upregulated in iPS-hFFib
(red). (B) Downregulated genes in iPS-hFFib (green).
Found at: doi:10.1371/journal.pone.0008975.s001 (0.06 MB TIF)
Figure S2 Unique set of genes (A) Upregulated in iPS-hASC. (B)
Downregulated in iPS-hASC.
Found at: doi:10.1371/journal.pone.0008975.s002 (0.07 MB TIF)
Figure S3 Unique set of genes (A) Upregulated in iPS-hNFib. (B)
Downregulated in iPS-hNFib.
Found at: doi:10.1371/journal.pone.0008975.s003 (0.07 MB TIF)
Figure S4 Unique set of genes (A) Upregulated in iPS-hKT. (B)
Downregulated in iPS-hKT.
Figure 7. Residual signatures of the genes (downregulated in both hiPSCs and donor cells compared to hESC) involved in human
embryonic stem cell pluripotency. (A) Expression fold-change in iPS-hFFib and hFFib. (B) Expression fold-change in iPS-hASC and hASC. (C)
Expression fold-change in iPS-hNFib and hNFib. (D) Expression fold-change in iPS-hKT and hKT.
doi:10.1371/journal.pone.0008975.g007
Donor Cell Memory in hiPS Cell
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Table S1 Functional analysis of the upregulated genes in (A)
iPS-hFFib and hFFib; (B) iPS-hASC and hASC; (C) iPS-hNFib
and hNFib and (D) iPS-hKT and hKT
Found at: doi:10.1371/journal.pone.0008975.s005 (0.18 MB
XLS)
Table S2 Functional analysis of the downregulated genes in (A)
iPS-hFFib and hFFib; (B) iPS-hASC and hASC; (C) iPS-hNFib
and hNFib and (D) iPS-hKT and hKT
Found at: doi:10.1371/journal.pone.0008975.s006 (0.17 MB
XLS)
Table S3 Functional analysis of the (A1) upregulated genes in
iPS-hFFib designating a unique hiPSC state; (A2) downregulated
genes in iPS-hFFib designating a unique hiPSC state. (B1)
upregulated genes in iPS-hASC designating a unique hiPSC state;
(B2) downregulated genes in iPS-hASC designating a unique
hiPSC state. (C1) upregulated genes in iPS-hNFib designating a
unique hiPSC state; (C2) downregulated genes in iPS-hNFib
designating a unique hiPSC state. (D1) upregulated genes in iPS-
hKT designating a unique hiPSC state; (D2) downregulated genes
in iPS-hKT designating a unique hiPSC state.
Found at: doi:10.1371/journal.pone.0008975.s007 (0.12 MB
XLS)
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